2024-10-19 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis:

**1. Performance Comparison with S&P 500 (VOO):**

Gilead Sciences Inc. (GILD) is a biopharmaceutical company focused on developing and commercializing treatments for HIV, hepatitis C, and oncology.  

GILD's cumulative return over the provided period is -10.4%, significantly lagging behind the S&P 500 (VOO) at 137.88%. The performance gap is substantial, with a relative divergence of -148.28, indicating that GILD has underperformed the S&P 500 by a significant margin.

**2. Recent Price Action:**

* **Closing price:** $86.72
* **5-day Moving Average:** $86.34
* **20-day Moving Average:** $84.79
* **60-day Moving Average:** $80.16

GILD's stock price is currently trading above all three moving averages, suggesting a potential short-term uptrend. However, the 5-day moving average being relatively close to the closing price might indicate a possible consolidation phase.

**3. Technical Indicators:**

* **RSI:** 68.0 - This indicates the stock is approaching overbought territory. 
* **PPO:** -0.04 - This suggests a potential slowdown in momentum or a possible reversal.
* **Delta_Previous_Relative_Divergence:** -1.63 - This indicates a short-term downward trend in relative divergence.
* **Expected_Return:** 0.0% - This suggests that GILD is not expected to outperform the S&P 500 in the long term (2 years+).

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue        |
|------------|----------|-----------------|
| 2024-08-08 | 1.29     | 6.95 B$         |
| 2024-05-08 | -3.34    | 6.69 B$         |
| 2023-11-07 | 1.75     | 7.05 B$         |
| 2023-08-04 | 0.84     | 6.60 B$         |
| 2024-08-08 | 0.84     | 6.60 B$         | 

The most recent earnings report for GILD (Q2 2024) showed an EPS of $1.29, exceeding analyst expectations of $1.06. Revenue also came in above estimates at $6.95 billion versus $6.85 billion expected. 

**5. News and Recent Issues:**

Recent market outlook for GILD is mixed. While analysts point to strong Q2 earnings and the company's focus on developing new treatments in oncology and inflammation, concerns remain regarding the potential impact of generic competition for its key products.

**Analyst Opinions and Performance Highlights:**

* **FINBOLD:** GILD's performance highlights include its robust portfolio of treatments for infectious diseases and its growing presence in the oncology market. However, concerns persist regarding its dependency on a few key products and the potential for price erosion.
* **Other analysts:** Several analysts have issued price targets for GILD ranging from $75 to $100, reflecting a mixed sentiment towards the company's future prospects.

**6. Overall Analysis:**

While GILD's recent earnings were strong, the company faces significant challenges. The stock has significantly underperformed the market in recent years, and its reliance on a few key products exposes it to potential generic competition. The stock's current technical indicators suggest a potential short-term uptrend, but the overall outlook remains uncertain.

**7. Conclusion:**

GILD's recent earnings performance provides some optimism, but its long-term performance remains uncertain. The company faces various challenges, including generic competition and dependency on a few key products. Given the mixed sentiment and the potential for volatility, investors should carefully consider the risks and rewards before investing in GILD.  
